<DOC>
	<DOCNO>NCT00468858</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness two different formulation investigational dengue vaccine ( T-DEN ) placebo vaccine two dos give six month apart adult child .</brief_summary>
	<brief_title>A Study Two Doses WRAIR Dengue Vaccine Administered Six Months Apart Healthy Adults Children</brief_title>
	<detailed_description>In study , child adults multiple site Puerto Rico randomly allocate receive one two T-DEN formulation placebo . Subjects stratify age group ( specific number subject 4 age group [ 12 month 50 year age ] enrol ) . The study include 6 schedule visit 4 scheduled venipuncture . Safety follow-up dengue may require unscheduled visit venipuncture . &gt; Multiple DEN virus serotypes endemic Puerto Rico resident consider risk dengue . The result phase II study provide basis identify vaccine formulation elicit neutralize antibody four dengue virus serotypes high proportion vaccine recipient . The immunogenic well tolerated candidate formulation identify study consider advancement phase III development . &gt;</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe and/or parents/guardians comply requirement protocol ( e.g. , completion diary card , return followup visit ) enrol study . A healthy male nonpregnant female 12 month ( mths ) 50 year ( yr ) age time first vaccination ; Free obvious health problem establish medical history physical examination enter study ; For child : 23mths age , full compliance United States Advisory Committee Immunization Practices ( U.S. ACIP ) recommend childhood immunization schedule ; Written inform consent obtain subject parent/guardian assent subject 720 yr age ; If subject female , must nonchildbearing potential , i.e . either premenarcheal , surgically sterilize one year postmenopausal ; , childbearing potential , must abstinent use adequate contraceptive precaution ( i.e . intrauterine contraceptive device ; condom spermicide combination , oral contraceptive equivalent hormonal contraception , e.g . progestin implantable , cutaneous hormonal patch injectable contraceptive ) 30 day ( dy ) prior vaccination , negative pregnancy test within 48 hrs prior vaccination must agree continue precaution 60 dys completion vaccination series . Any child begin menarche study period must follow precaution list , menarche 60 dys second vaccine dose . Pregnant lactate female ; Female planning become pregnant planning discontinue abstinence contraceptive precaution ; History neurological behavioral disorder seizure , exception single febrile seizure childhood ; History allergic disease/reaction likely exacerbate component vaccine ; Acute chronic , clinically significant pulmonary , cardiovascular , hepatic , renal , hematologic endocrine functional defect , determine physical examination laboratory test ; Any confirm suspected immunosuppressive immunodeficient condition ; Acute disease time enrollment ( acute disease define presence moderate severe illness without fever ) ; note vaccine administer person minor illness diarrhea , mild upper respiratory infection without lowgrade febrile illness , i.e. , equivalent oral temperature &lt; 37.5°C/ &lt; 99.5°F . Chronic hepatomegaly , right upper quadrant abdominal pain tenderness ; Chronic splenomegaly , leave upper quadrant abdominal pain tenderness ; Use investigational nonregistered drug vaccine study vaccine within 30 dy precede first dose study vaccine/placebo plan use study period ; Planned administration vaccine foreseen study protocol period start 30 dy dose study vaccine end 30 dy ; exception standard infant child `` inactivate '' vaccine inactivate influenza vaccine administer adult child ; A plan move location prohibit participate trial 12 mth duration ; Chronic administration ( define 14 dy ) immunosuppressant immunemodifying drug within 90 dy precede first dose plan administration study period . For corticosteroid , mean prednisone , equivalent , 0.5 mg/kg/day . Inhaled topical steroid allow ; Administration immunoglobulins and/or blood product within 90 dy precede first dose plan administration study period ; Hypertension ; Chest pain , palpitation , dizziness , shortness breath unrelated asthma , arrhythmias friction rub ; Any chronic systemic drug therapy continue study period ( except vitamin/mineral supplement , routine treatment gastroesophageal reflux ) ; Potential adult volunteer , parent potential child volunteer , easy access fix mobile telephone ; History chronic alcohol consumption and/or drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Dengue</keyword>
	<keyword>Virus</keyword>
	<keyword>Live-attenuated</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Dengue viral infection</keyword>
	<keyword>Dengue Vaccine</keyword>
</DOC>